CDKN2B and neoplasm: These authors found that the promoter region of CDKN2B is hypermethylated in a very small percentage of cases (7%) and that methylation in CDKN2B was not associated with patient survival or with any clinicopathological characteristic, including tumor grade, cell proliferation activity, and responsiveness to adjuvant therapy.